Drugs / ALC-2203-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07061925 | Apr → Nov 2025 | bronchitis | Korea Arlico Pharm. Co., Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALC-2203-2 | “This group receives ALC-2203-2 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.” NCT07061925 ↗ |